Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of Metformin and Glimepiride (AWARD-2: Assessment of Weekly AdministRation of LY2189265 in Diabetes-2)

Next Previous
Trial Profile

A Randomized, Open-Label, Parallel-Arm, Noninferiority Comparison of the Effects of Two Doses of LY2189265 and Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes on Stable Doses of Metformin and Glimepiride (AWARD-2: Assessment of Weekly AdministRation of LY2189265 in Diabetes-2)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dulaglutide (Primary) ; Glimepiride; Insulin glargine; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms AWARD-2
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 01 Apr 2022 Results of post-hoc pooled analysis of six studies (AWARD-1, -2, -3, -6, -8 and -9) assessing association between treatment with dulaglutide and glycaemic variability in adult patients with type 2 diabetes mellitus, published in the Diabetes, Obesity and Metabolism.
  • 16 Dec 2021 This trial has been completed in France, according to European Clinical Trials Database record.
  • 16 Jun 2020 Results from AWARD- 2 and AWARD-9 presented at the 80th Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top